Immunoregulatory T cells in cancer immunotherapy

Bibliography

• DURKIN HG, WAKSMAN BH: Thymus and tolerance. Is regulation the major function of the thymus? Immunol Rev (2001) 182:33–57.
   Google Scholar
• WALKER LS, ABBAS AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev Immunol (2002) 2:11–19.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. (1995) 155:1151–1164.
   Google Scholar
• SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. (2001) 182:18–32.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review from investigators who were pioneers in describing the importance of CD4+CD25+ T cells to the control of autoimmunity.
   Google Scholar
• BAECHER-ALLAN C, BROWN JA, FREEMAN GJ, HAFLER DA: CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol (2001) 167(3):1245–1253.
   PubMed Web of Science ®Google Scholar
• DIE CKMANN D, PLOTTNER H, BERCHTOLD S, BERGER T, SCHULER G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. (2001) 193:1303–1310.
   PubMed Web of Science ®Google Scholar
• NG WF, DUGGAN PJ, PONCHEL F et al: Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 98:2736–2744.
   PubMed Web of Science ®Google Scholar
• •Detailed description of the functional activity of human peripheral blood CD4+CD25+ T cells.
   Google Scholar
• TAAMS LS, SMITH J, RUSTIN MH, SALMON M, POULTER LW, AKBAR AN: Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur: j Immunol (2001) 31:1122–1131.
   PubMed Web of Science ®Google Scholar
• KUNIYASU Y, TAKAHASHI T, ITOH M,SHIMIZU J, TODA G, SAKAGUCHI S: Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. hat. Immunol (2000) 12:1145–1155.
   Web of Science ®Google Scholar
• PAPIERNIK M, BANZ A: Natural regulatory CD4 T cells expressing CD25. Microbes Infect. (2001) 3:937–945.
   PubMed Web of Science ®Google Scholar
• WING K, EKMARK A, KARLSSON H, RUDIN A, SURI-PAYER E: Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology (2002) 106:190–199.
   PubMed Web of Science ®Google Scholar
• MCHUGH RS, WHITTERS MJ, PICCIRILLO CA et al: CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 16:311–323.
   PubMed Web of Science ®Google Scholar
• ITOH M, TAKAHASHI T,SAKAGUCHI N et al.: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol (1999) 162:5317–5326.
   Google Scholar
• PAPIERNIK M, DE MORAES ML, PONTOUX C, VASSEUR F, PENIT C: Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int. Inonunol. (1998) 10:371–378.
   PubMed Web of Science ®Google Scholar
• ROMAGNOLI P, HUDRISIER D, VAN MEERWIJK JP: Preferential recognition of self antigens despite normal thymic deletion of CD4 (-F) CD 25 (-F) regulatory T cells.Irionunol. (2002) 168:1644–1648.
   PubMed Web of Science ®Google Scholar
• SEVACH EM: Regulatory T cells in autoimmunity. Ann. Rev Irionunol (2000) 18:423–449.
   PubMedGoogle Scholar
• JORDAN MS, BOESTEANU A, REED AJ et al.: Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Innnunol (2001) 2:301–306.
   PubMed Web of Science ®Google Scholar
• SUTO A, NAKAJIMA H, IKEDA K et al.: CD4(+)CD25(+) T-cell development is regulated by at least 2 distinct mechanisms. Blood. (2002) 99:555–560.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, KUNIYASU Y, TODA M et al.: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Inonunol. (1998) 10:1969–1980.
   PubMed Web of Science ®Google Scholar
• YAMAGIWA S, GRAY JD,HASHIMOTO S, HORWITZ DA: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.Irionunol. (2001) 166:7282–7289.
   PubMed Web of Science ®Google Scholar
• IELLEM A, MARIANI M, LANG R et al: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. (2001) 194:847–853.
   PubMed Web of Science ®Google Scholar
• •One of the few papers on chemokines that direct migration of CD4+CD25+ T cells. This line of research should receive more attention in the future.
   Google Scholar
• THORNTON AM, SHEVACH EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. Inonunol. (2000) 164:183–190.
   Google Scholar
• POWRIE F, CARLINO J, LEACH MW, MAUZE S, COFFMAN RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper Type 1-mediated colitis by CD45RB(low) CD4+ T cells. J. Exp. Med. (1996) 183:2669–2674.
   PubMed Web of Science ®Google Scholar
• SEDDON B, MASON D: Regulatory T cells in the control of autoimmunity: theessential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. ./. Exp. Med. (1999) 189:279–288.
   PubMed Web of Science ®Google Scholar
• STEPHENS LA, MOTTET C, MASON D, POWRIE F: Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. I Innnunol. (2001) 31:1247–1254.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, SCHMITT E, STASSEN M, TUETTENBERG A, KNOP J, ENK AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. 1. Exp. Med. (2001) 193:1285–1294.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, KITANI A,STROBER W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. (2001) 194:629–644.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO CA, LETTERIO JJ, THORNTON AM et al: CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor betal production and responsiveness. J. Exp. Med. (2002) 196:237–246.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, SCHMITT E,KAKIRMAN H, STASSEN M, KNOP J, ENK AH: Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med. (2002) 196:255–260.
   PubMed Web of Science ®Google Scholar
• DIECKMANN D, BRUETT CH, PLOETTNER H, LUTZ MB,SCHULER G: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 1-producing, contact-independent Type 1-like regulatory T cells. J. Exp. Med. (2002) 196:247–253.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, TAGAMI T,YAMAZAKI S, et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associatedantigen 4.j Exp. Med. (2000) 192:303–310.
   Google Scholar
• READ S, MALMSTROM V, POWRIE F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. I Exp. Med (2000) 192:295–302.
   PubMed Web of Science ®Google Scholar
• ERMANN J, SZANYA V, FORD GS, PARAGAS V, FATHMAN CG, LEJON K: CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. Inonunol. (2001) 167:4271–4275.
   Google Scholar
• CEDERBOM L, HALL H, IVARS F: CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. Innnunol. (2000) 30:1538–1543.
   PubMed Web of Science ®Google Scholar
• SIMARK-MATTSSON C,DAHLGREN U, ROOS K: CD4+CD25+ T Lymphocytes in human tonsils suppress the proliferation of CD4+CD25- tonsil cells. Scandj Inonunol. (2002) 55:606–611.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO CA, SHE VACH EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. Inonunol. (2001) 167:1137–1140.
   Google Scholar
• ZHANG X, IZIKSON L, LIU L, WEINER HL: Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. I Innnunol. (2001) 167:4245–4253.
   Google Scholar
• DIEDERICHSEN AC, ZEUTHEN J, CHRISTENSEN PB, KRISTENSEN T: Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur. J. Cancer (1999) 35:721–726.
   PubMed Web of Science ®Google Scholar
• WOO EY, YEH H, CHU CS et al: Cuttingedge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. Inonunol. (2002) 168:4272–4276.
   Google Scholar
• WOO EY, CHU CS, GOLETZ TJ et al:Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61:4766–4772.
   PubMed Web of Science ®Google Scholar
• •Description of the presence of CD4+CD25+ T cells in tumours which raises important questions about how these cells may impair tumour immune responses.
   Google Scholar
• SHIMIZU J, YAMAZAKI S,SAKAGUCHI S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. Inonunol. (1999) 163:5211–5218.
   Google Scholar
• •Important paper which along with [40] demonstrates how removing CD4+CD25+ T cells, even transiently, can ameliorate immunological non-responsiveness to tumours in murine models.
   Google Scholar
• ONIZUKA S, TAWARA I, SHIMIZU J,SAKAGUCHI S, FUJITA T,NAKAYAMA E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. (1999) 59:3128–33.
   Google Scholar
• •Demonstrates that multiple tumour cell lines can be rejected following CD4+CD25+ depletion.
   Google Scholar
• TANAKA H, TANAKA J,KJAERGAARD J, SHU S: Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.Immunother. (2002) 25:207–217.
   PubMed Web of Science ®Google Scholar
• STEITZ J, BRUCK J, LENZ J, KNOP J, TUTING T: Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer. Res. (2001) 61:8643–8646.
   PubMed Web of Science ®Google Scholar
• SUTMULLER RP,VAN DUIVENVOORDE LM,VAN ELSAS A et al.: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Exp. Med. (2001) 194:823–832.
   Google Scholar
• KUZEL TM: DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. Clin. Lymphoma. (2000)l\(Suppl. 1):533–536.
   Google Scholar
• TCHEKMEDYIAN S, GLASPY J, KORMAN A, KELER T, DEO Y, DAVIS TA: MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma. Proc. Am. Soc. Clin. Oncol (2002) 21:15a. Abstract 56.
   Google Scholar
• DAVIS TA, TCHEKMEDYIAN S, KORMAN A, KELER T, DEO Y, SMALL EJ: MDX-010 (human anti-CTLA4): a Phase I trial in hormonerefractory prostate carcinoma (HRPC). Proc. Am. Soc. Clin. Oncol (2002) 21:19a. Abstract 74.
   Google Scholar
• ANTONY PA, RESTIFO NP: Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? Immunother.(2002) 25:202–206.
   PubMed Web of Science ®Google Scholar
• GAVIN MA, CLARKE SR, NEGROU E, GALLEGOS A, RUDENSKY A: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat. Immunol (2002) 3:33–41.
   PubMed Web of Science ®Google Scholar